UCB SA (OTCMKTS:UCBJF) Sees Large Decline in Short Interest

UCB SA (OTCMKTS:UCBJF) was the target of a large decline in short interest during the month of June. As of June 15th, there was short interest totaling 704,696 shares, a decline of 37.2% from the May 31st total of 1,121,617 shares. Based on an average daily volume of 831 shares, the short-interest ratio is presently 848.0 days. Approximately 0.4% of the company’s stock are short sold.

UCB Price Performance

Shares of OTCMKTS:UCBJF opened at $307.59 on Friday. UCB has a 1 year low of $194.76 and a 1 year high of $345.39. The firm has a fifty day moving average price of $292.49 and a 200 day moving average price of $300.57. The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33.

UCB Company Profile

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.